Will the ubiquitin system furnish as many drug targets as protein kinases?
Protein phosphorylation and protein ubiquitination regulate most aspects of cell life, and defects in these control mechanisms cause cancer and many other diseases. In the past decade, protein kinases have become one of the most important classes of drug targets for the pharmaceutical industry. In contrast, drug discovery programs that target components of the ubiquitin system have lagged behind. In this Perspective, we discuss the reasons for the delay in this pipeline, the drugs targeting the ubiquitin system that have been developed, and new approaches that may popularize this area of drug discovery in the future.
Sir James Black Centre, Dundee, Scotland, UK. p.cohen@dundee.ac.uk
Philip
P
Cohen
Marianna
M
Tcherpakov
D000818:Animals; D055808:Drug Discovery; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism; D025801:Ubiquitin / Q000378:metabolism*; D044767:Ubiquitin-Protein Ligases / Q000037:antagonists & inhibitors; D054875:Ubiquitination / Q000187:drug effects*
D047428:Protein Kinase Inhibitors; D011506:Proteins; D025801:Ubiquitin; D044767:Ubiquitin-Protein Ligases